deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03879135

A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)

A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)

Sponsor: Baxalta now part of Shire

Conditions Von Willebrand Disease (VWD)
Interventions rFVIII rVWF
Updated 18 times since 2019 Last updated: Aug 13, 2025 Started: Apr 1, 2019 Primary completion: Jan 30, 2025 Completion: Jan 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Von Willebrand Disease (VWD) and is currently completed. Baxalta now part of Shire leads this study, which shows 18 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Mar 2020 · 10 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Mar 2022 · 11 months · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jul 2023 · 14 months · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Mar 2025 · 4 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 9 months · monthly snapshot

Change History

18 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  4. Nov 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE3

▶ Show 13 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  2. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  3. Sep 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  4. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  5. May 2022 — Jul 2023 [monthly]

    Recruiting PHASE3

  6. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE3

  7. Apr 2021 — Mar 2022 [monthly]

    Recruiting PHASE3

  8. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  9. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    Status: Enrolling By Invitation → Recruiting

  10. May 2020 — Jul 2020 [monthly]

    Enrolling By Invitation PHASE3

    Status: Recruiting → Enrolling By Invitation

  11. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE3

  12. May 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  13. Apr 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baxalta now part of Shire
  • Takeda Development Center Americas, Inc.
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Aurora, United States , Bron, France , Charleston, United States , Cincinnati, United States , Cleveland, United States , Columbus, United States , Florence, Italy , Frankfurt, Germany , Gainesville, United States and 19 more locations